That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

Sridhar Kosaraju Biography and Net Worth

Director of 10x Genomics

Sri Kosaraju has been a Board member of 10x Genomics since March 2019. He currently serves as President and CFO of Penumbra (NYSE: PEN), a global healthcare company focused on innovative therapies. Mr. Kosaraju joined Penumbra in 2015, serving as CFO and Head of Strategy until his promotion to President and CFO in 2019. Prior to joining Penumbra, he had over 16 years of experience in investment banking. Mr. Kosaraju worked for J.P. Morgan Securities LLC (J.P. Morgan) from 1999 until 2015, where he held a variety of positions, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Mr. Kosaraju received a B.S in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).

What is Sridhar Kosaraju's net worth?: The estimated net worth of Sridhar Kosaraju is at least $46,060.56 as of August 23rd, 2021. Mr. Kosaraju owns 3,458 shares of 10x Genomics stock worth more than $46,061 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Kosaraju may own. Learn More about Sridhar Kosaraju's net worth.
How do I contact Sridhar Kosaraju?: The corporate mailing address for Mr. Kosaraju and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected]. Learn More on Sridhar Kosaraju's contact information.
Has Sridhar Kosaraju been buying or selling shares of 10x Genomics?: Sridhar Kosaraju has not been actively trading shares of 10x Genomics in the last ninety days. Most recently, Sridhar Kosaraju sold 1,500 shares of the business's stock in a transaction on Wednesday, November 24th. The shares were sold at an average price of $150.06, for a transaction totalling $225,090.00. Learn More on Sridhar Kosaraju's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, insiders at the sold shares 17 times. They sold a total of 57,543 shares worth more than $2,038,285.55. The most recent insider tranaction occured on August, 22nd when CEO Serge Saxonov sold 6,749 shares worth more than $152,054.97. Insiders at 10x Genomics own 10.0% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 8/22/2024.

Sridhar Kosaraju Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2021	Sell	1,500	$150.06	$225,090.00
10/25/2021	Sell	1,500	$166.32	$249,480.00
9/23/2021	Sell	1,500	$159.04	$238,560.00
8/23/2021	Sell	1,500	$162.06	$243,090.00	3,458
7/23/2021	Sell	1,500	$183.67	$275,505.00
6/23/2021	Sell	1,500	$199.95	$299,925.00	3,458
5/24/2021	Sell	1,500	$161.16	$241,740.00	2,833
4/23/2021	Sell	1,500	$193.08	$289,620.00
3/23/2021	Sell	1,500	$174.63	$261,945.00	2,833

Sridhar Kosaraju Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $13.32

$13.16

$13.80

50 Day Range

MA: $17.91

$13.18

$23.48

2 Week Range

Now: $13.32

$12.95

$57.90

Volume

1,406,057 shs

Average Volume

2,048,265 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Trump said you could learn something from this man

From Wide Moat Research | Ad

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.